stockaxis

AMI Organics Ltd

Quarterly Result - Q4FY25

AMI Organics Ltd

Pharmaceuticals & Drugs

Current

CMP
Rs. 1196.90
Rating:
Hold
May 02, 2025

Previous

Rating:
Hold

Stock Info

BSE
543349
NSE
AMIORG
Bloomberg
AMIORG:IN
Reuters
AMIO.NS
Sector
Pharmaceuticals & Drugs
Face Value (Rs)
5
Equity Capital (Rs cr)
41
Mkt Cap (Rs cr)
9514.81
52w H/L (Rs)
1322.00 - 504.00
Avg Daily Vol (BSE+NSE)
1,343,953

Shareholding Pattern

(as on 31-Mar)
%
Promoter
35.96
FIIs
16.48
DIIs
18.31
Public & Others
29.22
Source: Ace equity, stockaxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
-6.10
-6.03
91.36
Sensex
5.07
4.30
7.90
Source: Ace equity, stockaxis Research

Indexed Stock Performance

AMI Organics Ltd Sensex
AMI Organics Ltd
Source: Ace equity, stockaxis Research

Financial Highlights:

Particulars (Rs. in cr) Q4FY25 Q4FY24 YoY (%) Q3FY25 QoQ (%)
Revenue from operations 308.00 225.00 37.00% 275.00 12.00%
EBITDA 85.00 43.00 98.00% 68.00 25.00%
EBITDA Margin (%) 27.60% 19.11% 849 bps 24.73% 287 bps
PAT 63.00 26.00 144.00% 45.00 40.00%
EPS (%) 7.80 3.43 127.00% 5.61 39.00%

Source: Company Filings; stockaxis Research

Q4FY25 Result Highlights
AMI Organics showcased robust financial performance for the quarter ended Q4FY25. Consolidated net sales rose 37% YoY to Rs.308 cr as compared to Rs.225 cr registered in the same quarter of preceding fiscal driven by healthy growth in the pharma intermediate sales which jumped to Rs.270 cr (up 14% QoQ and 44% YoY). This jump could be due to a jump in CDMO sales to Fermion. Specialty chemicals revenue fell slightly to Rs. 36 cr and Rs.36 cr in Q3FY25, down 1% QoQ while up 1% YoY). In Q4FY25, pharma intermediate EBITDA margin was 24.5% and speciality chemicals margin was 14.7%. The gross margin for the quarter improved to 47.3% up 734 bps YoY and 108 bps QoQ. On the operational front, consolidated EBITDA witnessed remarkable growth of 97% YoY to Rs.85 cr while EBITDA margin for the quarter was at 27.5% on account of a sharp jump in CDMO sales and resultant positive operating leverage. PAT registered a staggering growth of 144% to Rs.63 cr.

Key Conference call takeaways

Guidance

  • Management has guided for a 25% revenue growth in FY26. This is set to be driven by continued growth in the CDMO business, improvement in sales of generic molecules aided by several patent expirations in CY25 and CY26 and electrolyte additives production from H2FY26.
  • The company also highlighted that due to the nature of the company’s business cycle, Q1 could be the weakest quarter with top line steadily increasing sequentially till Q4, which is always the strongest quarter. As a result, H1FY26 might appear softer with 40% top line contribution while the remaining 60% for the year will come in H2FY26.
  • The management believes that EBITDA margin will improve in FY26 (compared to FY25). In FY25, EBITDA margin for the advanced pharma intermediate was 24.5% while specialty chemicals EBITDA margin was 14.7%; blended total EBITDA margin was ~23%. The specialty chemicals segment margin is expected to be at the current level in FY26.
  • The company has also guided for Rs.1000 cr CDMO sales by FY28. – The management said it was seeing increasing enquiries in the CDMO space with India being a viable alternative to China. It added that commercialization of a new CDMO contract remains on track with the company in the qualification stage with the customer. Also, revenue contribution from this new CDMO contract is expected from 2HFY26.

Capex
The management has indicated a capex of Rs.200 cr for FY26, comprising spillover capex of Rs.130 cr for electrolyte additives and the rest for maintenance and a pilot plant at Sachin. This will be fully funded through QIP proceeds and internal accruals. Capex for FY25 stood at Rs.195 cr primarily for the Ankleshwar facility, solar plant and electrolyte additives capacity. Block 1 at Ankleshwar is set to be commissioned in Q1FY26 with a 10.8MW solar plant already commissioned at the Sachin facility.

Other Key Highlights

  • The company said its generic business has been growing at a good pace and further growth is expected in FY26. This is set to be driven by expiration of patents for several molecules in CY25 and CY26.
  • The company said commodity volume, including that of paraben and salicylic acid, in specialty chemicals saw 25% YoY growth in FY25. It expects similar growth in the business in FY26.
  • The company said it is on track to complete the electrolyte additives capex at Jhagadia in H1FY26 with production expected to start in 2HFY26. It plans to gradually ramp up operations to reach optimum utilization in 3 years.
  • The company is planning to set up a pilot plant at Sachin, which will enable it to expedite scale-up of new products from R&D as well as manufacture new products under the CRAMS model.
  • The company added 6-8 customers for Baba Fine Chem.

Outlook & valuation

Ami Organics delivered an impressive set of earnings for the quarter ended Q4FY25. We like the company given its wide product portfolio in pharmaceutical intermediates, diversification efforts into other specialty chemical spaces, strong client relations across geographies, and robust financials. It is well placed to tap the opportunity in the fast-growing specialty chemical market by leveraging its strong R&D capabilities and expanding its product portfolio. We believe that the near to medium-term growth would be driven by advanced intermediates for pharma innovators. AMI is present across the value chain of the intermediates business, from supplying NCE to innovators, to providing a wide range of products with different routes of synthesis and different levels of intermediates. As one of the biggest manufacturers of intermediates for the target therapies, AMI is in a unique position to cross-sale new molecules to existing clients. Their unique business model positions them perfectly to be the preferred suppliers for innovators as well as big generic pharma companies. The company is gradually executing Fermion’s contract in the first block of the Ankleshwar unit. It is meant for advanced pharmaceutical intermediates for the API Darolutamide and would finally ramp up in FY26. Hence, we believe Ami Organics is well-placed to capitalize on domestic and global opportunities.

We believe that the pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, positioning the company favourably for sustained long-term growth. Management has guided for 25% growth for FY26. Strong sales from Fermion contracts,  the commercialization of an additional CDMO contract, significant expansion in the generic intermediate portfolio, and contributions from electrolyte additives projected from FY26E are some growth drivers for the company. We believe that the near-term growth would be driven by the advanced intermediates business. Operating margins are expected to improve further in FY26 due to operating leverage and also due to energy cost savings, following the setting up of a captive solar plant. At CMP of Rs.1161.80, the stock is trading at 33x FY27E. We maintain HOLD rating on the stock.

Consolidated Financial statements

Profit & Loss statement

Particulars (Rs. in cr) Q4FY25 Q4FY24 YoY (%) Q3FY25 QoQ (%)
Revenue from operations 308.00 225.00 37.00% 275.00 12.00%
COGS 162.00 135.00 20.00% 148.00 9.00%
Gross Profit 146.00 90.00 62.00% 127.00 15.00%
Gross Margin (%) 47.40% 40.00% 740 bps 46.18% 122 bps
Employee benefit expenses 23.00 17.00 35.00% 22.00 5.00%
Other expenses 38.00 30.00 27.00% 37.00 3.00%
EBITDA 85.00 43.00 98.00% 68.00 25.00%
EBITDA Margin (%) 27.60% 19.11% 849 bps 24.73% 287 bps
Depreciation expenses 7.00 5.00 40.00% 6.00 17.00%
EBIT 78.00 38.00 105.00% 62.00 26.00%
Finance costs 0.60 2.00 -70.00% 0.70 -14.00%
Other Income 6.00 1.00 500.00% 2.00 200.00%
PBT 83.00 37.00 125.00% 63.00 32.00%
Tax expenses 20.00 12.00 67.00% 18.00 11.00%
PAT 63.00 26.00 144.00% 45.00 40.00%
EPS (%) 7.80 3.43 127.00% 5.61 39.00%